JPMorgan raised the firm’s price target on GSK (GSK) to 1,500 GBp from 1,440 GBp and keeps an Underweight rating on the shares. Published first on TheFly – the ultimate source for real-time ...

Arizona Attorney General Kris Mayes on Thursday sued pharmaceutical manufacturer GlaxoSmithKline for engaging in deceptive and unfair practices that endangered vulnerable asthma patients ...

The lawsuit claims GlaxoSmithKline replaced Flovent with an identical generic version, hurting patients whose insurance wouldn't cover it and costing taxpayers money. Arizona Attorney General Kris ...

Harvey Jones has something to celebrate after a positive set of results boosted the GSK share price after a disappointing run. Is there scope for more growth? The content of this article is ...

GSK's business development team have been working overtime of late, with three R&D deals announced in the last few days across Alzheimer's disease and cancer. The Alzheimer's agreement – with ...

GSK licensed the drug from longstanding partner Ionis as part of a two-drug deal in 2019, paying $25 million upfront with milestone payments taking the value of the deal up to $262 million.

Teva Pharmaceutical Industries Ltd. ADR-2.66% $19.77B ...